Drug treatment of lipid disorders. [N Engl J Med. 1999] - PubMed

loading

Lipid-lowering drug use and cardiovascular events after myocardial infarction. [Ann Pharmacother. 2002]
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Klungel OH, Heckbert SR, de Boer A, Leufkens HG, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM. Ann Pharmacother. 2002 May; 36(5):751-7.
Review Pharmacology department: pharmacologic approaches to abnormal blood lipids. [J Cardiovasc Nurs. 2000]
Review Pharmacology department: pharmacologic approaches to abnormal blood lipids.
Gylys KH. J Cardiovasc Nurs. 2000 Jan; 14(2):9-15.
Adverse effects of the treatment for hyperlipidemia. [Cardiol Clin. 1986]
Adverse effects of the treatment for hyperlipidemia.
Malinow MR. Cardiol Clin. 1986 Feb; 4(1):95-103.
Review Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. [Curr Atheroscler Rep. 2005]
Review Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
Ansell BJ. Curr Atheroscler Rep. 2005 Feb; 7(1):29-33.
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol. [Prev Cardiol. 2010]
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Phillips W, Schaefer S. Prev Cardiol. 2010 Spring; 13(2):69-71.

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry. [Vasc Health Risk Manag. 2013]
Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry.
Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K. Vasc Health Risk Manag. 2013; 9:71-80. Epub 2013 Feb 21.
The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism. [J Clin Invest. 2013]
The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism.
Deng Y, Wang ZV, Tao C, Gao N, Holland WL, Ferdous A, Repa JJ, Liang G, Ye J, Lehrman MA, et al. J Clin Invest. 2013 Jan 2; 123(1):455-68. Epub 2012 Dec 21.
Cholesterol: its regulation and role in central nervous system disorders. [Cholesterol. 2012]
Cholesterol: its regulation and role in central nervous system disorders.
Orth M, Bellosta S. Cholesterol. 2012; 2012:292598. Epub 2012 Oct 17.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
BioSystems
Pathways and biological systems (BioSystems) that cite the current articles. Citations are from the BioSystems source databases (KEGG and BioCyc).
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Drug treatment of lipid disorders.
Drug treatment of lipid disorders.
N Engl J Med. 1999 Aug 12 ;341(7):498-511.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed